Q4 2024 Immunovia AB (publ) Earnings Call Transcript

Feb 25, 2025 / 02:00 PM GMT

Release Date Price: $0.052065

Transcript

Key Points

Positve

Immunovia AB (LTS:0G8X) successfully completed the clinical validation of their next-generation test, showing high sensitivity and specificity.
The new test reduces reliance on the CA 199 biomarker, allowing results for all patients, including those who previously could not be tested.
The next-generation test can be used across all races and ethnicities, addressing previous limitations with the IMRA test.
The company has reduced costs by transitioning to a widely used industry-standard ELISA platform, lowering both fixed and variable costs.
Immunovia AB (LTS:0G8X) raised significant funds through a rights issue and warrants, demonstrating strong investor interest and securing financial stability into the second half of 2025.

Negative

The company faces challenges in commercializing the test, requiring strategic partnerships to expand market reach effectively.
There is uncertainty regarding the impact of US healthcare policies under the Trump administration, which could affect funding and regulatory processes.
The share price has not reflected the positive results of the next-generation test, possibly due to market conditions and recent financial activities.
The company anticipates some volatility in cash burn due to the timing of clinical studies and commercialization efforts.
Immunovia AB (LTS:0G8X) needs to secure FDA approval in the coming years, which may be delayed due to reduced staffing at the FDA.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMMNOV.ST - Immunovia AB (publ)
Q4 2024 Immunovia AB (publ) Earnings Call
Feb 25, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you so much, and a good morning, and a good afternoon, and a warm welcome to all of you joining Imanovvia's conference call following the 4th quarter results for 2024.

Presenting in the call is our CEO Jeff Borshedding and myselfarron Alquist, CFO of the company.

And as you already heard, this presentation will be followed by a Q&A session, which will be guided by our operator.

After we have closed today's call, you will find the presentation and the recording on our website.

And with that, I'd like to hand over to Jeff. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.